Abstract

Serological Criteria for Mild, Moderate and Severe Atrophy in Atrophic Gastritis

Sergey Mikhailovich Kotelevets and Sergey Anatolievich Chekh

The study was carried out in a group of 360 dyspeptic Helicobacter pylori-infected patients. These patients were tested for markers of atrophy of the mucous membrane of the antrum section (gastrin-17) and corpus of stomach (pepsinogen-1). The markers were detected via the test panel for immune-enzyme analysis - "GastroPanel". All the 360 patients underwent the upper gastrointestinal endoscopy with subsequent biopsy of the antral and corpus mucosa. These markers were identified for a group of patients with severe atrophic gastritis and for a group of patients with mild and moderate atrophy. The level of the gastrin-17 was determined for the number of patients with mild, moderate and severe antral atrophic gastritis, which was identified with the use of upper gastrointestinal endoscopy followed by a biopsy of the antral mucosa. The level of the gastrin-17 in the serum was: mild antral atrophy - 7 ≤ pmol/L 0 10, moderate antral atrophy – 4 ≤ pmol/L <7, severe antral atrophy - 0 ≤ pmol/L < 4, no atrophy - 10 ≤ pmol/L. The level of the pepsinogen-1 was determined for the number of patients with mild, moderate and severe corpus atrophic gastritis, which was identified with the use of upper gastrointestinal endoscopy followed by a biopsy of the corpus mucosa. The bounds of the pepsinogen-1 level in the serum were: mild corpus atrophy - 15 ≤ µg/L <25, moderate corpus atrophy – 9 ≤ µg/L <15, severe corpus atrophy - 0 ≤ µg/L <9, no corpus atrophy - 25 ≤ µg/L. Rising of the effectiveness of serological screening considering the lines of serological markers severe atrophy and detected patients with high risk gastric cancer allows to avoid the upper gastrointestinal endoscopy